Enrolment For Phase 2 Clinical Study In Multiple Sclerosis Complete

Angiotech Pharmaceuticals, Inc. announced today that it has completed enrolment of its 189-patient, Phase 2 clinical study for the use of Micellar Paclitaxel in the treatment of patients with secondary progressive multiple sclerosis (SPMS). To date, there have been no drug-related serious adverse events reported in the patients enrolled in the nine-month study.

The double blind, placebo-controlled study is being conducted at nine centres across Canada. The primary objective of the study is to determine the difference in new lesion activity in the Micellar Paclitaxel treatment groups relative to the control group during the treatment phase as demonstrated by magnetic resonance imaging (MRI). Patients are receiving placebo or Micellar Paclitaxel at 50 mg/m2 or 75 mg/m2 every four weeks for a total of six doses (with a 12-week follow-up period).

Multiple sclerosis is a chronic inflammatory and progressive disease, with debilitating neurological symptoms occurring over a period of several years. Although the disease does not result in early death, it disables patients by disturbing vision, strength, balance and sensation, as well as causing fatigue and cognitive problems. The estimated 2000 U.S. treatment market for all MS patients is US$704 million.

Many pharmaceutical therapies are currently under clinical development such as systemic Micellar Paclitaxel for secondary progressive multiple sclerosis (Phase 2).

На первую страницу